Role of olmesartan in combination therapy in blood pressure control and vascular function

Carlos M Ferrario
Ronald D Smith
Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

Abstract: Angiotensin receptor blockers have emerged as a first-line therapy in the management of hypertension and hypertension-related comorbidities. Since national and international guidelines have stressed the need to control blood pressure to <140/90 mmHg in uncomplicated hypertension and <130/80 mmHg in those with associated comorbidities such as diabetes or chronic kidney disease, these goal blood pressures can only be achieved through combination therapy. Of several drugs that can be effectively combined to attain the recommended blood pressure goals, fixed-dose combinations of angiotensin receptor blockers and the calcium channel blocker amlodipine provide additive antihypertensive effects associated with a safe profile and increased adherence to therapy. In this article, we review the evidence regarding the beneficial effects of renin–angiotensin system blockade with olmesartan medoxomil and amlodipine in terms of blood pressure control and improvement of vascular function and target organ damage.

Keywords: amlodipine, angiotensin receptor blockers, angiotensin-converting enzyme 2, hypertension, renin–angiotensin system

Introduction

The 33rd report on the Health Status in the United States estimates that essential hypertension affects 17.9% of the age-adjusted, 20-year-old or older white subjects and up to 26% of male African Americans (http://www.cdc.gov/nchs/data/hus/hus09.pdf). Numerous large-scale clinical trials have documented the benefits of strict blood pressure control in preventing hypertension-related cardiovascular events. It is clear that the benefit of blood pressure reduction to 120/80 mmHg in non-diabetic patients will be associated with a large reduction in the occurrence of strokes and fatal and nonfatal ischemic heart diseases. Since single-drug therapy is often not able to lower blood pressure to these ideal values, recent recommendations now emphasize the need for combination therapy to achieve these blood pressure goals. Although no definitive evidence is available as to which combination therapy will most effectively achieve strict blood pressure control and reduction in target organ damage, the increased use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and the calcium channel blocker (CCB) amlodipine, widely prescribed alone or in combination in most countries in the world, favors their use.

Evidence-based medicine from large controlled clinical trials supports the use of these drugs, although the long-term benefit of any one combination over the others remains to be established. In this context, the Avoiding Cardiovascular Events through COMbination Therapy in Patients LiVing with Systolic Hypertension (ACCOMPLISH) study showed that the combination of benazepril and amlodipine resulted in outcome
benefits greater than those observed in subjects medicated with benazepril and hydrochlorothiazide (HCTZ) despite similar blood pressure reductions.4,5 Although both ACE inhibitors and ARBs have a definitive role in preventing the consequences of increased renin–angiotensin system activity in cardiac, vascular, and renal functions, enhanced tolerability and the more specific effects of ARBs on suppressing the binding of angiotensin II (Ang II) to the subtype 1 (AT₁) receptor should favor the use of ARBs over blockers of ACE. This article summarizes the evidence for the combined use of the AT₁ selective receptor antagonist, olmesartan medoxomil, with amlodipine on blood pressure control and target organ damage. Additional information regarding the pharmacological and clinical response to olmesartan administration are reviewed elsewhere.6–9

**Pharmacodynamics of olmesartan and amlodipine**

Olmesartan medoxomil is a highly selective ARB with pharmacokinetic characteristics that determine high binding to AT₁ receptors and lasting effects on arterial pressure.10,11 The medoxomil ester of olmesartan facilitates its bioavailability as the oral bioavailability of the active product RNA-6270 is less than 4.5%.12 In bovine adrenal cells, the displacement of ¹²⁵I-Ang II by olmesartan has a half maximal inhibitory concentration (IC₅₀) value of 7.7 nM, a displacement value significantly lower than that of losartan (92 nM) and its active metabolite EXP3174 (16 nM). Figure 1 shows that the affinity of olmesartan for AT₁ receptors is high when compared with that of other ARBs. Furthermore, the displacement of olmesartan by Ang II in Hill’s plots shows that the active drug behaves as a competitive antagonist of AT₁ receptors.13 Pharmacokinetic properties of olmesartan support its efficacy and long duration of action when given to experimental animals and humans. Additional information on pharmacokinetics of olmesartan and its mode of action are discussed elsewhere.8,9,14

The antihypertensive actions of olmesartan are potentiated when used in combination with either thiazide diuretics or CCBs. Amlodipine is a potent dihydropyridine CCB having a high degree of ionization, high oral bioavailability (60%–65%), and peak plasma concentrations attainable within 6–8 hours after oral administration. Like other dihydropyridine CCB, amlodipine selectively inhibits calcium (Ca²⁺) influx across cell membranes in cardiac and vascular smooth muscle with a greater effect on the latter.15 Rohatagi et al16 reported the pharmacokinetics of olmesartan medoxomil and amlodipine besylate alone and in a fixed-dose combination in five phase I crossover studies in healthy volunteers. The similarity of the mean steady-state pharmacokinetics of olmesartan and amlodipine at doses of 40 and 10 mg, respectively, their drug concentration–time curves, and the maximum observed plasma drug concentrations within their prespecified bioequivalence (80%–125%) showed that they were well suited to coadministration in a fixed-dose combination.16 Furthermore, coadministration of amlodipine besylate and
olmesartan medoxomil, as commercially available separate dosage forms, for 10 days showed no evidence of any negative pharmacokinetic drug–drug interactions. The additive mechanisms of action of the single-dose form of olmesartan/amlodipine on long-term hemodynamic and neurohormonal systems controlling blood pressure have not been studied. Results from the direct effects of olmesartan or amlodipine on cardiac and vascular structures and hypertension-induced remodeling suggest complementary actions. Olmesartan induces a reduction in peripheral vascular resistance that is associated with no changes in heart rate or cardiac output and increases in plasma renin activity (see Schindler and Ferrario for review). In the EUROpean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUROPA trial), olmesartan was found to lower the serum levels of high-sensitivity C-reactive protein, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and human monocyte chemoattractant protein-1 (MCP-1). A further reevaluation of the EUROPA trial showed that the vasoprotective effects of olmesartan were associated with decreases in plasma osteopontin concentrations. The anti-inflammatory effects of AT1 receptor blockade with olmesartan may contribute to the observation that this drug can prevent the progression of atherosclerosis in nonhuman primates. Additional vasculotrophic effects of olmesartan in the protection of vascular endothelial function have been reviewed recently. Although the long-term effect of olmesartan on the plasma and tissue concentrations of Ang II requires further study, a report by Ichikawa et al showed that blockade of AT1 receptors may not be associated with the typical increase in plasma Ang II concentrations, as observed with other ARBs. This clinical study may be tentatively explained by the observation that AT1 blockade upregulates the activity and tissue expression of ACE 2, a homolog of ACE that acts as a monokarboxypeptidase degrading Ang II into the vasodilator and antitrophic peptide angiotensin-(1-7) [Ang-(1-7)]. In keeping with these findings, an experimental study in the stroke-prone rat suggested that olmesartan may act as an inhibitor of ACE through the stimulation of Ang-(1-7) actions and release of nitric oxide.

The beneficial effects of olmesartan on the prevention of vascular remodeling and carotid artery atherosclerotic plaque progression in subjects with hypertension are now documented. The Multicentre Olmesartan Atherosclerosis Regression Evaluation (MORE) study was a double-blind trial conducted in patients with hypertension who are at increased cardiovascular risk (presence of carotid wall thickening and a defined atherosclerotic plaque), using noninvasive two- and three-dimensional ultrasonography. The trial compared the effects of a 48-month treatment based on either olmesartan medoxomil or atenolol on common carotid intima-media thickness and plaque volume (PV). Large PVs (≥33 µL) were significantly reduced over the 102-week treatment period only in those subjects assigned to the olmesartan-based therapy. In agreement with these findings, administration of olmesartan to subjects with diabetes was associated with reduced arterial stiffness while amlodipine had no effect.

The Vascular Improvement with Olmesartan Study (VIOS) enrolled 100 subjects with stage I hypertension without diabetes, to evaluate whether an olmesartan-based therapeutic regimen could reverse vascular hypertrophy independent of the magnitude of blood pressure lowering. The trial compared the effects of olmesartan-based therapy versus atenolol-based therapy on blood pressure control and changes in wall/media ratio (W/L) from small resistance arterioles obtained from these patients through the technique of gluteal biopsies. Biopsies were available from 22 atenolol recipients (100 mg/day), 27 olmesartan medoxomil recipients (40 mg/day), and 11 normal volunteer controls. Additional antihypertensive medications (HCTZ 12.5–25 mg/day, amlodipine 5–10 mg/day, or hydralazine 50–100 mg twice daily) were dispensed to achieve blood pressure control below 140/90 mmHg. Overall, patients in the atenolol-based regimen group required more medications versus patients randomized to the olmesartan-based group. Furthermore, a greater percentage of patients assigned to the olmesartan-based therapy achieved and maintained an ideal blood pressure of <120/80 mmHg at 4 weeks (24% in the olmesartan-based therapy vs 8% in those assigned to the atenolol-based therapy [P < 0.05]). At the completion of the 52-week period, comparable decreases in arterial pressure resulting in the physiological levels of blood pressure (≤120/80 mmHg) were observed in patients assigned to each of the two regimens. Normalization of blood pressure, however, was associated with the regression of vascular hypertrophy only in those subjects assigned to the olmesartan-based therapy (Figure 2). In these subjects, the reduction in W/L ratio of small resistance vessels (from 14.9% to 11.1%; P < 0.01) was numerically equivalent to the W/L ratio determined in the subset of normotensive volunteers from whom subcutaneous small arteriole resistance vessels were obtained. Since the addition of HCTZ and amlodipine were required in more than 59% of the subjects and no differences existed in the dosing and time periods in which these agents were incorporated to the treatment regimen...
for both arms of the study, the data demonstrated that the selective effect of AT₁ receptor blockade in the reversal of vascular hypertrophy in small resistance vessels was directly responsible for the reduction of peripheral vascular resistance.³²,³³ Furthermore, noninvasive measurements of central aortic pressure and determination of the augmentation index by applanation tonometry³⁵ showed decreases in the indices of vascular compliance only on those subjects receiving the olmesartan-based therapy.³² On the other hand, a study that investigated the role of cellular oxidant stress and inflammation on patients with hypertension and the cardiometabolic syndrome showed comparative effects induced by treatment with either olmesartan or amlodipine.³⁶ A small sample size and the presence of comorbidities may have contributed to the reported conclusions.³⁶

**Clinical studies**

A series of studies have documented the effective control of arterial pressure achieved with the daily fixed-dose administration of a single tablet of olmesartan/amlodipine. A multicenter, double-blind, randomized, placebo-controlled, parallel-group, factorial study, lasting 8 weeks and enrolling 1,940 subjects with stage 1 and stage 2 hypertension, evaluated the blood pressure response to placebo, amlodipine (5–10 mg/day), olmesartan (10, 20, and 40 mg/day), and the fixed combination of olmesartan and amlodipine at doses of 5/10, 5/20, 5/40, 10/10, 10/20, and 10/40 mg/day.³⁷ At the highest dose combination of olmesartan/amlodipine (40/10 mg/day), the reduction in systolic and diastolic blood pressures amounted to 28.5 and 19.4 mmHg, respectively.³⁷

The decreases in arterial pressure were significantly greater than those obtained with either olmesartan or amlodipine when given alone.³⁷ The beneficial effects of the single-tablet combination were associated with increased target blood pressure of <140/90 mmHg. Although all treatment regimens in the Combination of Olmesartan medoxomil and Amlodipine besylate in Controlling High blood pressure (COACH) study were well tolerated and were free of major side effects, the occurrence of pedal edema was less in those subjects medicated with the fixed-dose combination of 40/10 mg of olmesartan/amlodipine (23.5%) than in those subjects medicated with amlodipine alone (36.8%). The reduction in peripheral edema in response to the addition of an ARB to a CCB is a product of the concurrent vasodilator effect of Ang II blockade inducing venular capillary dilatation, thus diminishing the pressure gradient across the peripheral microcirculation.³⁸

A trial performed in Europe compared the effectiveness of a single-pill combination of olmesartan and amlodipine in a randomized, double-blind, parallel-group, multicenter trial in patients with moderate to severe hypertension (systolic blood pressure...
pressure \( [SBP] \geq 160 \text{ mmHg and diastolic blood pressure} \) \( [DBP] \geq 100 \text{ mmHg} \).\(^{39} \) Nonresponders to an open-label monotherapy phase with olmesartan (8 weeks at 20 mg/day) were randomized to 20 mg/day olmesartan plus placebo, the fixed-dose combination of 20 mg/day olmesartan plus 5 mg/day amlodipine, or 20 mg/day olmesartan plus 10 mg/day amlodipine for an additional 8 weeks.\(^{37} \) The primary end point evaluated the intention-to-treat population of all subjects with hypertension who received at least one dose of the double-blind study medication, had baseline measures of sitting DBP, and achieved at least one postrandomization measure of DBP > 140/90 mmHg. Potential confounders due to the use of the less rigorous statistical approach of last observation carried forward for missing data during the double-blind period were compensated by the inclusion of an observed case approach in which the last observation was not carried forward. Of the 1,519 screened subjects, 722 patients entered the open-label phase of the study with 20 mg/day olmesartan. The 538 subjects who completed this phase of the study were randomized to the 8-week double-blind period of one of the three interventions. The blood pressure of <140/90 mmHg after the 8-week double-blind period was achieved in 28.5%, 44.5%, and 45.8% of subjects randomized to olmesartan/placebo, 20/5 mg/day olmesartan/amlodipine, and 20/10 mg/day olmesartan/amlodipine, respectively.\(^{39} \) A post hoc analysis showed that the number of subjects reaching a DBP of <90 mmHg were greater in those using the fixed-dose combinations of olmesartan/amlodipine.\(^{39} \) In addition, the study showed that the combination therapy was associated with an earlier reaching of their goal blood pressure when compared with the monotherapy phase. These data are in agreement with another study in which the combination of 10–40 mg/day olmesartan with 5 mg/day amlodipine for 8 weeks reduced the mean SBP and DBP by 16.8 and 9.6 mmHg, respectively.\(^{40} \)

SBP is a predictor of increased cardiovascular risk.\(^{41} \) In a post hoc analysis of changes in sitting SBP in patients treated with 40 mg of olmesartan plus 5–10 mg/day amlodipine,\(^{40} \) the combination therapy was shown to be most effective in reducing SBP in the subjects with highest levels of SBP.\(^{42} \) As reviewed elsewhere,\(^{33} \) this combination therapy is superior to the single-agent administration in other high-risk populations, such as African Americans,\(^{43} \) obese, and patients with diabetes. The predominant effect of improvement in insulin resistance and reduced oxidative stress seems to be related to blockade of Ang II receptors.\(^{45}–{49} \)

Presence of chronic kidney disease aggravates the odds of cardiovascular events in patients with hypertension.\(^{50} \) The potential for renoprotective effects of combining a CCB with olmesartan in elderly patients (age 65–85 years) with chronic kidney disease was investigated in a crossover study using an open-label, randomized design with albutaminurin (creatinine > 5 mg/g).\(^{51} \) Following a 2-week run in observation period, the subjects were randomized to receive a starting dose of benidipine (4 mg/day) or amlodipine combined with olmesartan (5/10 mg/day). Three months later, the patients were switched from benidipine to amlodipine and followed-up for an additional 3 months. Benidipine is a dihydropyridine CCB that induces efferent arteriolar dilation through blockade of both L- and T-type calcium channels.\(^{52,53} \) Combination of olmesartan with either CCBs produced comparable decreases in arterial blood pressure, whereas the combination of benidipine and olmesartan achieved slightly greater statistically significant decreases in albumin excretion.\(^{31} \) The Randomized Olmesartan and Diabetes Prevention (ROADMAP) study determined the factors correlating with albumin excretion rates across the range of normoalbuminuric values in patients with type 2 diabetes using olmesartan medoxomil.\(^{54,55} \)

There is evidence that the administration of olmesartan is the key driver in achieving the target blood pressure in patients with stage II hypertension\(^{48} \) and reducing the effects of hypertension in vascular remodeling.\(^{31,32} \) A multicenter, 12-week study compared the efficacy, safety, and tolerability of a combination of olmesartan medoxomil/HCTZ with that of benazepril plus amlodipine besylate in patients with stage II hypertension.\(^{57} \) The data showed that the primary efficacy end point of change in mean seated SBP at week 12 was significantly greater with olmesartan medoxomil/HCTZ than with benazepril plus amlodipine besylate.\(^{57} \) These findings are in agreement with other studies documenting the efficacy of the combination of olmesartan/HCTZ in subjects with hypertension and in those with isolated systolic hypertension.\(^{44,58–60} \) As reviewed by Quan et al\(^{61} \) a multifactorial analysis of the published studies reported that the daily combination of 40 mg olmesartan and 25 mg HCTZ produced greater blood pressure reductions than with the administration of 300 mg irbesartan/25 mg HCTZ, 80 mg telmisartan/12.5 mg HCTZ, and 160 mg valsartan/25 mg HCTZ.\(^{62} \) The addition of HCTZ to patients receiving a fixed-dose combination of olmesartan/amlodipine (40/5–10 mg/ day) increased the overall proportion of patients reaching the goal blood pressure.\(^{63} \) In an additional study that focused on reaching the blood pressure goals rather than the responder rates, with the combination of olmesartan medoxomil, amlodipine, and HCTZ, 90% of patients with
stage 2 hypertension reached the blood pressure of <140/90 mmHg and 81% patients attained <130/85 mmHg.64

Long-term outcome studies as to the benefit of the combination of olmesartan/amlopidine in the prevention of cardiovascular events are not yet available. To meet this objective, an on-going study will evaluate whether high-dose ARB monotherapy is superior to the combination therapy of ARB plus CCB in the prevention of cardiovascular morbidity and mortality in elderly Japanese high-risk patients with hypertension (OlmeSartan and Calcium Antagonists Randomized [OSCAR] Study).65

Conclusions
The importance of blood pressure control in the prevention of cardiovascular events is well established. Given the relative success in achieving appropriate blood pressure control in the general population, effective drug combinations as first-line therapy can meet the need to attain blood pressure levels <140/90 mmHg in uncomplicated hypertension and ≤130/80 mmHg in subjects with diabetes or in those in whom hypertension is accompanied by chronic kidney disease. Although published guidelines advocate the combination of a thiazide diuretic with another antihypertensive agent as initial therapy, emerging evidence suggests that the association of a CCB with either an ACE inhibitor or an ARB may be a safer and more effective combination.66 Evidence for this approach is buttressed by the recent publication of the ACCOMPLISH study.67 In this study, the combination of the ACE inhibitor benazepril with the CCB amlodipine was more effective than the combination of benazepril with HCTZ in reducing the primary composite end point of cardiovascular events and death from cardiovascular causes over the 36-month mean follow-up period.67 The combination of olmesartan/amlopidine in a fixed-dose combination has proven to be effective in controlling blood pressure in patients with stage 1 and stage 2 hypertension.4,37,38,44,56,66–73 Their additive anti-hypertensive effect is associated with complimentary actions that in part may be related to the buffering of the reactive increase in renin–angiotensin system activity triggered by the vasodilator action of amlopidine.74

Among the advantages of fixed combination therapy, several studies suggest that this approach overcomes issues related to side effects, patient and physician inertia, the proportion of subjects classified as resistant hypertension, and cost-effectiveness issues such as co-pays.43 In several observational studies, fixed-dose combinations were associated with higher rates of compliance, persistence, and adherence to treatment regimens.75–82 A meta-analysis of 15 published studies with a total of 32,331 patients concluded that fixed-dose combinations of antihypertensive agents were associated with increased compliance and no changes in the frequency of adverse events when compared with free drug components given separately.80

Interest in the effect of the circadian rhythm of blood pressure in terms of its association with the occurrence of cardiovascular events posits the question as to whether single-pill, fixed-dose combinations may provide greater benefit when administered at bedtime. Although the effectiveness of such a chronotherapeutic approach remains unexplored for single-pill, fixed-dose combinations, Minutolo et al83 reported that in nondipper subjects with chronic kidney disease changing the timing of antihypertensive therapy decreases nocturnal blood pressure and proteinuria. As reviewed by Stergiou et al84 morning administration of single- or fixed-dose combinations of drugs have been used in assessing the efficacy of antihypertensive therapy. In bedtime dosing of treatment as used in the Controlled-Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial, chronotherapeutical dosing of verapamil failed to blunt the early morning surge in blood pressure.85 In contrast, the bedtime dosing of ramipril in the Heart Outcomes Prevention Evaluation (HOPE) trial has been suggested to partially account for the vascular benefits found in this study.86 The efficacy of olmesartan medoxomil in controlling blood pressure over a 24-hour period showed that the ARB was more effective than losartan and valsartan in maintaining lower levels of blood pressure for mean daytime and nighttime ambulatory blood pressure.87 Although further work will be necessary to evaluate these possibilities, it is undeniable that the use of a single-pill, fixed-dose combination at bedtime should be explored in well-controlled clinical trials.

Acknowledgments
In addition to the support provided by NHLBI grant PO1 HL051952, the authors gratefully acknowledge the grant support provided by Unifi, Inc., Greensboro, NC, and Farley-Hudson Foundation, Jacksonville, NC.

Disclosure
Carlos M Ferrario receives compensation for speaking and consulting with Daiichi Sankyo Corporation, Novartis, Inc., Forest Research, Bristol-Myers Squibb, Takeda, and Merck Inc.

References

706

submit your manuscript | www.dovepress.com
Dovepress

Vascular Health and Risk Management downloaded from https://www.dovepress.com/ by 54.191.40.80 on 04-Apr-2017
For personal use only.


Vascular Health and Risk Management downloaded from https://www.dovepress.com/ by 54.191.40.80 on 04-Apr-2017
For personal use only.